Healthcare and Psychosocial Needs in Achondroplasia Across the Lifespan: Developmental Functioning, Multidisciplinary Care, and Family-Centered Outcomes.
Achondroplasia requires lifelong, multidisciplinary management to address its complex healthcare and psychosocial needs, with vosoritide being one of several components in care.
Where it sits
this study against the rest of the vosoritide corpusSummary and findings
This narrative review examines the healthcare and psychosocial needs of individuals with achondroplasia across their lifespan. It highlights the importance of multidisciplinary care and the introduction of vosoritide as a disease-modifying option. The review emphasizes the need for comprehensive clinical surveillance and support throughout various life stages.
Abstract
<h4>Background/objectives</h4>Achondroplasia is the most common skeletal dysplasia and the leading genetic cause of disproportionate short stature. Although its biological basis involves gain-of-function variants in the FGFR3 gene, achondroplasia is a lifelong multisystem disorder associated with neurological, respiratory, orthopedic, otolaryngological, cardiovascular, oral, functional, and psychosocial complications. This narrative review aims to synthesize the evidence on developmental and adaptive functioning, age-specific healthcare needs, multidisciplinary service delivery, transition to adult care, psychosocial well-being, caregiver burden, and patient- and family-centered outcomes in achondroplasia across the lifespan.<h4>Methods</h4>A narrative literature review was conducted using PubMed/MEDLINE, Scopus, Web of Science Core Collection, and CINAHL, with Google Scholar used as a supplementary source. Studies published between January 2010 and July 2026 were considered, together with earlier clinically relevant reports. Evidence addressing prenatal and postnatal diagnosis, age-specific manifestations, neurological and respiratory complications, orthopedic and otolaryngological care, cardiometabolic risk, growth monitoring, multidisciplinary management, transition to adult services, disease-modifying therapy, quality of life, and caregiver burden was evaluated.<h4>Results</h4>The clinical priorities of achondroplasia change substantially across the lifespan. Infancy is characterized by an increased risk of foramen magnum stenosis, cervicomedullary compression, hypotonia, and sleep-disordered breathing, whereas orthopedic deformities, chronic pain, reduced mobility, spinal stenosis, hearing impairment, obesity, and cardiovascular risk become increasingly relevant during later childhood, adolescence, and adulthood. Early diagnosis, condition-specific imaging, neurological and respiratory surveillance, growth monitoring, and coordinated specialist care are essential for preventing severe complications. Vosoritide has introduced a disease-modifying therapeutic option, but it does not replace comprehensive clinical surveillance, rehabilitation, orthopedic care, psychosocial support, or shared decision-making. Functional limitations, environmental barriers, treatment burden, and caregiver stress contribute substantially to reduced quality of life.<h4>Conclusions</h4>Achondroplasia should be managed as a lifelong multisystem condition rather than solely as a disorder of short stature. Standardized surveillance, multidisciplinary coordination, planned transition to adult care, and patient- and family-centered management are essential for improving function, autonomy, long-term health outcomes, and quality of life.
Background
This paper addresses the comprehensive healthcare and psychosocial needs of individuals with achondroplasia, a condition known for its complex, multisystem implications. Prior literature has identified various complications associated with achondroplasia, but there is a need for a synthesized understanding of these issues across different life stages. This study is significant as it aims to inform better management strategies and care coordination for affected individuals.
Methods
The study is a narrative literature review that utilized databases such as PubMed/MEDLINE, Scopus, Web of Science Core Collection, and CINAHL, with Google Scholar as a supplementary source. It considered studies published from January 2010 to July 2026, along with earlier clinically relevant reports. The review evaluated evidence on various aspects of achondroplasia, including diagnosis, complications, management, and quality of life.
Results
The review indicates that the clinical priorities for managing achondroplasia change significantly throughout a person's life. Specific complications such as foramen magnum stenosis and sleep-disordered breathing are more prevalent in infancy, while orthopedic and cardiovascular issues become more prominent in later stages. Vosoritide is mentioned as a disease-modifying therapy, but its role is not quantified in terms of outcomes or effectiveness.
Interpretation
The findings suggest that while vosoritide may offer a new therapeutic avenue, the overall management of achondroplasia requires a multifaceted approach that includes regular surveillance and psychosocial support. The lack of specific quantitative findings regarding vosoritide limits the ability to assess its clinical significance compared to existing management strategies. The review highlights important confounds, including the narrative nature of the study and the absence of robust data on treatment outcomes.
Key findings
- Achondroplasia is associated with neurological, respiratory, orthopedic, otolaryngological, cardiovascular, oral, functional, and psychosocial complications.
- Infancy is characterized by increased risk of foramen magnum stenosis, cervicomedullary compression, hypotonia, and sleep-disordered breathing.
- Later childhood, adolescence, and adulthood see a rise in orthopedic deformities, chronic pain, reduced mobility, spinal stenosis, hearing impairment, obesity, and cardiovascular risk.
- Functional limitations, environmental barriers, treatment burden, and caregiver stress contribute substantially to reduced quality of life.
Limitations
- Narrative review without quantitative data.
- No specific outcomes reported for vosoritide.
- Focus on literature synthesis rather than original research.
- Potential publication bias in reviewed studies.